Therapeutic Asset Ratings

705 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
N-Acetyl-L-Cysteine Zellweger Syndrome	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Oral Restorative Microbiota Therapy Lung Adenocarcinoma	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Pembrolizumab Autologous Stem Cell Transplant	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Plerixafor Transplant Rejection	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Plerixafor Hemoglobinopathy	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Rapamycin Follicular Lymphoma	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Rapamycin Transplant Rejection	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Rapamycin Hemoglobinopathy	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Rapamycin Myelodysplastic Syndrome With Excess Blasts-1	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Romidepsin CBL Gene Mutation	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Romidepsin Chromosome Abnormality	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Romidepsin CNS Leukemia	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Romidepsin Dyskeratosis Congenita	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Romidepsin Fetal Hemoglobin	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Romidepsin Graft Failure	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Romidepsin Hemoglobinopathies	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Romidepsin Intrachromosomal Amplification of Chromosome 21	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Romidepsin Monosomy 7	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Romidepsin NF1 Mutation	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Romidepsin N-RAS Gene Amplification	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Romidepsin PTPN11 Gene Mutation	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Romidepsin Remission	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Romidepsin Severe Aplastic Anemia	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Romidepsin Somatic Mutation	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Romidepsin T Cell Receptor Alpha/Beta Depletion	Masonic Cancer Center, University of Minnesota	P2	CCC (53)

Showing 501 to 525 of 705 assets

PreviousPage 21 of 29Next